GENENTECH, INC for GENENTECH INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
R&D Tax Credit (H.R. 942), FDA Appropriations, PDUFA Reauthorization; general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned U.S. corporations; Worked to garner support for H.R. 942, the AmericanResearch and Competitiveness Act of 2011; Monitoring proposals on US tax treatment of foreign-owned U.S. corporations;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| ELI KOGAN | Assoc. Director |
Copyright/Patent/Trademark CPT
Cyber Security H.R. 942 American Research and Competitiveness Act of 2011, S.23: America Invents Act, H.R. 1249: Leahy-Smith America Invents Act; Patent Reform Act; H.R. 243 Patent Lawsuit Reform Act of 2011; H.R. 1249 Leahy-Smith America Invents Act S.23 - America Invents Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Director |
Health Issues HCR
Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA,stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapties. Issues related to the PPS ruel involving stroke guidelines. Implementation of the follow-on biologice provisions in P.L. 111-148- "Patient Protection and Affordable Care Act"; legislation on public health preparedness and response related to pandemic influenza. Influenz Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; FDA Approval and enforcement issues. Issues relating to S.3187, FDA Safety and Innovation Act. Issues relating to antibiotic development incentives in HR 2182 and S 1734, "Generating Antibiotic Incentives Now Act of 2011"; Prescription Drug User Fee Act (PDUFA) Reauthorization;Issues related to the implementationof the Affordable Care Act of 2010;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Director |
| ELI KOGAN | Director |
| EVAN MORRIS | VP Government Affairs |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus, issues relating comparative effectiveness and CMS coverage of FDA approved therapies. Legislation on public health preparedness and response related to pandemic influenza. Avastin-use in breast cancer treatment; general patent reform issues; implementation of the Affordable Care Act of 2010; Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. Monitor PDUFA reauthorization.; Monitor implementation of Medicare pharmaceutical coverage and reimbursement and 340B provisions if the Affordable Care Act; Advocacy related ensuring access to necessary medicines
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Director |
| ELI KOGAN | Assoc. Director |
| EVAN MORRIS | VP Government Affairs |
| KATHERINE RAAB | Director |
Budget/Appropriations BUD
FY13 Labor, HHS and Education Approporation related to preparedness for pandemic influenza, HIV/AIDS programs, heptatis screening, care and treatment, and access to breast cancer treatment; Following issues related to the budget and apropriations process FY13 appropriations for FDA as well as the potential outcomes fore negotiations on altering sequestration targets via legislation; Issues related to FDA and HHS program funding, FY13 Labor Health and Human Services, and Education, and Related agencies Appropriations bill; Budget/Appropriations (House and Senate Contact Only): Monitor FY13 appropriations process: FDA funding issues and drug approval/review oversight process. Monitor the potential outcomes for negotiations on altering sequestration targets via legislation. Monitor plans for issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders (R & D tax credit).
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Director |
| KATHERINE RAAB | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.